Literature DB >> 1764497

Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization.

A Amery1, W Birkenhäger, C J Bulpitt, D Clément, P De Leeuw, C T Dollery, R Fagard, A Fletcher, F Forette, G Leonetti.   

Abstract

The Syst-Eur Trial is a concerted action of the European Community's Medical and Health Research Programme. The trial is carried out in consultation with the World Health Organization, the International Society of Hypertension, the European Society of Hypertension and the World Hypertension League. This article describes the objectives and the protocol of Syst-Eur, a multicentre trial designed by the European Working Party on High Blood Pressure in the Elderly (EWPHE), to test the hypothesis that antihypertensive treatment of elderly patients with isolated systolic hypertension results in a significant change in stroke morbidity and mortality. Secondary endpoints include cardiovascular events, such as myocardial infarction and congestive heart failure. To be eligible patients must be at least 60 years old and have a systolic blood pressure averaging 160-219 mmHg with a diastolic pressure less than 95 mmHg. Patients must give their informed consent and be free of major cardiovascular and non-cardiovascular diseases at entry. The patients are randomized to active treatment or placebo. Active treatment consists of nitrendipine (10-40 mg/day), combined with enalapril (5-20 mg/day) and hydrochlorothiazide (12.5-25 mg/day), as necessary. The patients of the control group receive matching placebos. The drugs (or matching placebos) are stepwise titrated and combined in order to reduce systolic blood pressure by 20 mmHg at least to a level below 150 mmHg. Morbidity and mortality are monitored to enable an intention-to-treat and per-protocol comparison of the outcome in the 2 treatment groups. A one-year pilot trial (1989) showed that the protocol is practicable. The Ethics Committee therefore decided to start the definite study (1990), in which randomized patients will be followed for 5 years. Recruitment of new centres and of the required 3,000 patients will last 3 years (until 1993).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1764497     DOI: 10.1007/bf03324024

Source DB:  PubMed          Journal:  Aging (Milano)        ISSN: 0394-9532


  29 in total

1.  Recent outcome trials of newer antihypertensives.

Authors:  S Bakir; S Oparil
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

2.  Management of elderly patients with sustained hypertension.

Authors:  K Beard; C Bulpitt; H Mascie-Taylor; K O'Malley; P Sever; S Webb
Journal:  BMJ       Date:  1992-02-15

3.  Where are the guidelines for treating hypertension in elderly patients?

Authors:  K O'Malley; E O'Brien
Journal:  BMJ       Date:  1992-10-10

Review 4.  What is the clinical relevance of isolated systolic hypertension?

Authors:  J P Emeriau
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 5.  Treatment of hypertension in the elderly--the end of the story?

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1992-12       Impact factor: 3.727

6.  Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective.

Authors:  A E Fletcher; C J Bulpitt
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

7.  [Prevention of arteriosclerosis. Importance of the treatment of arterial hypertension].

Authors:  G Bönner; D B Gysan; G Sauer
Journal:  Z Kardiol       Date:  2005

Review 8.  The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

Authors:  C J Bulpitt; A E Fletcher; A Amery; J Coope; J G Evans; S Lightowlers; K O'Malley; A Palmer; J Potter; P Sever
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 9.  Prognostic significance of blood pressure in the very old. Implications for the treatment decision.

Authors:  C J Bulpitt; A E Fletcher
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 10.  Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials.

Authors:  Yi Chen; Lei Lei; Ji-Guang Wang
Journal:  Pulse (Basel)       Date:  2018-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.